Elevated plasma atrial natriuretic peptide concentrations in hypertensive patients with acute myocardial infarction.
BACKGROUND
Atrial natriuretic peptide (ANP) has been extensively studied in cardiovascular disorders in recent years. Particular attention has been paid to the role of ANP in the pathogenesis of hypertension and congestive heart failure and in the neurohormonal response to myocardial infarction. However, no published data are available on the significance of ANP in hypertensive patients with acute myocardial infarction.


METHODS
We studied the relationship between plasma ANP concentration and systolic blood pressure, diastolic blood pressure, left atrial dimension, left ventricular diastolic dimension and left ventricular mass index in patients with essential hypertension in the acute phase of myocardial infarction. Plasma ANP concentrations were determined at 0, 4, 8, 16, 24, 48 and 72 h after admission in 40 patients with a first myocardial infarction (18 hypertensive patients, group 1; 22 normotensive patients, group 2). Left atrial dimension and left ventricular diastolic dimension were assessed echocardiographically within the first 48 h of acute myocardial infarction.


RESULTS
Maximum and mean plasma ANP values at 0, 4, 8, 16, 24, 48, and 72 h as well as mean ANP concentrations within the 72 h period were higher in group 1 than in group 2 (P < 0.001). Plasma ANP concentration, left atrial dimension (r = 0.59) and left ventricular diastolic dimension (r = 0.56) were positively correlated in both groups.


CONCLUSIONS
Acute myocardial infarction is characterized by a more pronounced rise in plasma ANP concentration in hypertensive patients than in those without a history of hypertension. Plasma ANP concentration correlates with left heart chamber sizes.
Górecki
A
A
Department of Cardiology, Academy of Medicine, Warsaw, Poland.
Januszewicz
A
A
Opolski
G
G
Lapiński
M
M
Wocial
B
B
Ignatowska-Switalska
H
H
Słomka
K
K
Kochanowski
J
J
Stolarz
P
P
D000070:Acebutolol / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D009320:Atrial Natriuretic Factor / Q000097:blood*; D001794:Blood Pressure; D002303:Cardiac Output, Low / Q000097:blood / Q000150:complications; D003402:Creatine Kinase / Q000097:blood; D003404:Creatinine / Q000097:blood; D004452:Echocardiography; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006325:Heart Atria / Q000000981:diagnostic imaging / Q000473:pathology; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D007527:Isoenzymes; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D009543:Nifedipine / Q000627:therapeutic use; D011188:Potassium / Q000097:blood / Q000652:urine; D012964:Sodium / Q000097:blood / Q000652:urine
D007527:Isoenzymes; D000070:Acebutolol; D005665:Furosemide; D009320:Atrial Natriuretic Factor; D012964:Sodium; D003404:Creatinine; D003402:Creatine Kinase; D008790:Metoprolol; D009543:Nifedipine; D011188:Potassium